S&P 500   3,978.27 (+0.18%)
DOW   32,447.92 (+0.65%)
QQQ   308.36 (-0.81%)
AAPL   158.26 (-1.24%)
MSFT   276.44 (-1.47%)
META   202.11 (-1.89%)
GOOGL   102.66 (-2.64%)
AMZN   97.29 (-0.86%)
TSLA   190.59 (+0.09%)
NVDA   264.50 (-1.23%)
NIO   8.90 (-1.87%)
BABA   85.60 (-1.50%)
AMD   95.74 (-2.26%)
T   18.87 (+1.40%)
F   11.51 (+0.00%)
MU   59.65 (-2.47%)
CGC   1.89 (-0.71%)
GE   93.10 (+1.89%)
DIS   94.93 (+0.90%)
AMC   4.36 (-2.46%)
PYPL   73.40 (-0.65%)
PFE   40.31 (-0.20%)
NFLX   326.89 (-0.46%)
S&P 500   3,978.27 (+0.18%)
DOW   32,447.92 (+0.65%)
QQQ   308.36 (-0.81%)
AAPL   158.26 (-1.24%)
MSFT   276.44 (-1.47%)
META   202.11 (-1.89%)
GOOGL   102.66 (-2.64%)
AMZN   97.29 (-0.86%)
TSLA   190.59 (+0.09%)
NVDA   264.50 (-1.23%)
NIO   8.90 (-1.87%)
BABA   85.60 (-1.50%)
AMD   95.74 (-2.26%)
T   18.87 (+1.40%)
F   11.51 (+0.00%)
MU   59.65 (-2.47%)
CGC   1.89 (-0.71%)
GE   93.10 (+1.89%)
DIS   94.93 (+0.90%)
AMC   4.36 (-2.46%)
PYPL   73.40 (-0.65%)
PFE   40.31 (-0.20%)
NFLX   326.89 (-0.46%)
S&P 500   3,978.27 (+0.18%)
DOW   32,447.92 (+0.65%)
QQQ   308.36 (-0.81%)
AAPL   158.26 (-1.24%)
MSFT   276.44 (-1.47%)
META   202.11 (-1.89%)
GOOGL   102.66 (-2.64%)
AMZN   97.29 (-0.86%)
TSLA   190.59 (+0.09%)
NVDA   264.50 (-1.23%)
NIO   8.90 (-1.87%)
BABA   85.60 (-1.50%)
AMD   95.74 (-2.26%)
T   18.87 (+1.40%)
F   11.51 (+0.00%)
MU   59.65 (-2.47%)
CGC   1.89 (-0.71%)
GE   93.10 (+1.89%)
DIS   94.93 (+0.90%)
AMC   4.36 (-2.46%)
PYPL   73.40 (-0.65%)
PFE   40.31 (-0.20%)
NFLX   326.89 (-0.46%)
S&P 500   3,978.27 (+0.18%)
DOW   32,447.92 (+0.65%)
QQQ   308.36 (-0.81%)
AAPL   158.26 (-1.24%)
MSFT   276.44 (-1.47%)
META   202.11 (-1.89%)
GOOGL   102.66 (-2.64%)
AMZN   97.29 (-0.86%)
TSLA   190.59 (+0.09%)
NVDA   264.50 (-1.23%)
NIO   8.90 (-1.87%)
BABA   85.60 (-1.50%)
AMD   95.74 (-2.26%)
T   18.87 (+1.40%)
F   11.51 (+0.00%)
MU   59.65 (-2.47%)
CGC   1.89 (-0.71%)
GE   93.10 (+1.89%)
DIS   94.93 (+0.90%)
AMC   4.36 (-2.46%)
PYPL   73.40 (-0.65%)
PFE   40.31 (-0.20%)
NFLX   326.89 (-0.46%)
Positive News Sentiment  
NASDAQ:VBIV

VBI Vaccines - VBIV Stock Forecast, Price & News

$0.29
+0.00 (+1.16%)
(As of 03/27/2023 12:45 PM ET)
Add
Compare
Today's Range
$0.29
▼
$0.30
50-Day Range
$0.29
▼
$0.64
52-Week Range
$0.24
▼
$1.86
Volume
453,181 shs
Average Volume
889,461 shs
Market Capitalization
$74.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

VBI Vaccines MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
582.8% Upside
$2.00 Price Target
Short Interest
Bearish
6.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.28) to ($0.20) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

801st out of 995 stocks

Pharmaceutical Preparations Industry

390th out of 482 stocks

See Top Rated MarketRank™ Stocks Here

VBIV stock logo

About VBI Vaccines (NASDAQ:VBIV) Stock

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.

Receive VBIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

VBIV Stock News Headlines

March 18, 2023 | americanbankingnews.com
Analysts Offer Predictions for VBI Vaccines Inc.'s Q4 2023 Earnings (NASDAQ:VBIV)
March 17, 2023 | americanbankingnews.com
VBI Vaccines Inc. (NASDAQ:VBIV) Expected to Earn Q1 2023 Earnings of ($0.07) Per Share
March 27, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
March 15, 2023 | msn.com
VBI Vaccines Earnings Perspective: Return On Capital Employed
March 15, 2023 | finance.yahoo.com
VBI Vaccines Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
March 13, 2023 | finance.yahoo.com
VBI Vaccines Reports Full Year 2022 Financial Results
February 24, 2023 | usatoday.com
Mpox vaccine worked well, safely, CDC data shows. Committee votes to continue its use.
February 24, 2023 | abcnews.go.com
Flu vaccine worked well in season that faded fast, CDC says
March 27, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
February 24, 2023 | cnn.com
CDC advisers vote in favor of using mpox vaccine in future outbreaks
February 24, 2023 | nypost.com
First-ever RSV vaccine could be approved, roll out by August
February 23, 2023 | finance.yahoo.com
VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat
February 21, 2023 | forbes.com
First FDA-Approved RSV Vaccines Expected Later This Year: The Top Vaccines And Their Effectiveness
February 20, 2023 | usnews.com
Moderna Bows to Pressure, Says COVID-19 Vaccines Will Remain Free After Emergency Ends
February 15, 2023 | finance.yahoo.com
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
January 24, 2023 | finance.yahoo.com
Individual investors account for 55% of VBI Vaccines Inc.'s (NASDAQ:VBIV) ownership, while private equity firms account for 25%
January 23, 2023 | nypost.com
COVID vaccine may make Botox less effective: study
January 16, 2023 | abcnews.go.com
Companies look at increasing price of their COVID-19 vaccines. Bernie Sanders is not happy
January 12, 2023 | cnet.com
First Ever Honeybee Vaccine Approved to Target Deadly Global Disease
January 12, 2023 | nbcnews.com
A fake tweet spurred an anti-vaccine harassment campaign against a doctor
January 3, 2023 | usatoday.com
Fact check: Post falsely claims that FDA said Pfizer vaccines cause blood clots
December 17, 2022 | seekingalpha.com
VBIV VBI Vaccines Inc.
December 8, 2022 | finance.yahoo.com
VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults
December 6, 2022 | finance.yahoo.com
CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal
November 22, 2022 | finance.yahoo.com
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
November 11, 2022 | finance.yahoo.com
VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
November 4, 2022 | finance.yahoo.com
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Lags Revenue Estimates
See More Headlines
Receive VBIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

VBIV Company Calendar

Last Earnings
3/13/2023
Today
3/27/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VBIV
CUSIP
N/A
CIK
764195
Web
www.vbivaccines.com
Phone
(617) 830-3031
Fax
N/A
Employees
149
Year Founded
2001

Price Target and Rating

Average Stock Price Forecast
$2.00
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+600.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.44)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-113,300,000.00
Net Margins
-10,471.63%
Pretax Margin
-10,471.63%
Return on Equity
-115.47%
Return on Assets
-63.81%

Debt

Debt-to-Equity Ratio
0.76
Current Ratio
2.10
Quick Ratio
1.92

Sales & Book Value

Annual Sales
$1.08 million
Price / Sales
68.32
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.25 per share
Price / Book
1.14

Miscellaneous

Outstanding Shares
258,260,000
Free Float
233,723,000
Market Cap
$73.78 million
Optionable
Optionable
Beta
1.92

Social Links


Key Executives

  • Jeff Baxter
    President, Chief Executive Officer & Director
  • Christopher McNulty
    CFO, Director & Head-Business Development
  • Francisco Diaz-Mitoma
    Chief Medical Officer
  • David Evander Anderson
    Chief Scientific Officer
  • T. Adam Buckley
    Senior Vice President-Business Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













VBIV Stock - Frequently Asked Questions

Should I buy or sell VBI Vaccines stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VBIV shares.
View VBIV analyst ratings or view top-rated stocks.

What is VBI Vaccines' stock price forecast for 2023?

1 equities research analysts have issued 12 month price objectives for VBI Vaccines' stock. Their VBIV share price forecasts range from $2.00 to $2.00. On average, they anticipate the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 600.0% from the stock's current price.
View analysts price targets for VBIV or view top-rated stocks among Wall Street analysts.

How have VBIV shares performed in 2023?

VBI Vaccines' stock was trading at $0.3911 at the beginning of 2023. Since then, VBIV shares have decreased by 26.9% and is now trading at $0.2857.
View the best growth stocks for 2023 here.

When is VBI Vaccines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our VBIV earnings forecast.

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc. (NASDAQ:VBIV) issued its earnings results on Monday, March, 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01. The biopharmaceutical company earned $0.29 million during the quarter, compared to analysts' expectations of $1.98 million. VBI Vaccines had a negative trailing twelve-month return on equity of 115.47% and a negative net margin of 10,471.63%.

What ETF holds VBI Vaccines' stock ?

ETFMG Treatments Testing and Advancements ETF holds 56,036 shares of VBIV stock, representing 0.12% of its portfolio.

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

Who are VBI Vaccines' major shareholders?

VBI Vaccines' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cambridge Investment Research Advisors Inc. (1.29%), Charles Schwab Investment Management Inc. (0.57%), Renaissance Technologies LLC (0.27%), Captrust Financial Advisors (0.21%), Millennium Management LLC (0.15%) and Deutsche Bank AG (0.11%). Insiders that own company stock include Life Sciences Maste Perceptive, Nell Beattie and Perceptive Advisors Llc.
View institutional ownership trends.

How do I buy shares of VBI Vaccines?

Shares of VBIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $0.29.

How much money does VBI Vaccines make?

VBI Vaccines (NASDAQ:VBIV) has a market capitalization of $73.78 million and generates $1.08 million in revenue each year. The biopharmaceutical company earns $-113,300,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.

How many employees does VBI Vaccines have?

The company employs 149 workers across the globe.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The official website for the company is www.vbivaccines.com. The biopharmaceutical company can be reached via phone at (617) 830-3031 or via email at ir@vbivaccines.com.

This page (NASDAQ:VBIV) was last updated on 3/27/2023 by MarketBeat.com Staff